Vaxcyte (PCVX) Other Non-Current Assets (2019 - 2026)

Vaxcyte (PCVX) posted quarterly Other Non-Current Assets of $1.5 million for Q1 2026, up 11.14% year-over-year from $1.3 million in Q1 2025, and little changed quarter-over-quarter from $1.5 million in Q4 2025.

Vaxcyte (PCVX) Other Non-Current Assets (2019 - 2026) Analysis & Trends

Vaxcyte (PCVX) has reported Other Non-Current Assets for 8 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Other Non-Current Assets rose 11.14% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (up 11.14% YoY), while the FY2025 annual figure was $1.5 million, up 11.31% from the prior year.
  • Other Non-Current Assets steadied at $1.5 million in Q1 2026 per PCVX's latest filing, from $1.5 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $5.7 million in Q1 2022 and bottomed at $871000.0 in Q3 2022.
  • Historically, Other Non-Current Assets has averaged $1.8 million across 5 years, with a median of $1.3 million in 2024.
  • Annual changes were most pronounced in 2022 — Other Non-Current Assets surged 523.31% — and 2023, when it sank 84.63%.
  • Vaxcyte's Other Non-Current Assets stood at $871000.0 in 2022, then rose by 26.64% to $1.1 million in 2023, then grew by 19.4% to $1.3 million in 2024, then rose by 11.31% to $1.5 million in 2025, then changed by 0.0% to $1.5 million in 2026.
  • Business Quant data shows PCVX's Other Non-Current Assets at $1.5 million in Q1 2026, $1.5 million in Q4 2025, and $1.5 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 1.25 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 2.31 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 124.00 Mn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 42.45 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 109.58 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 18,237.65
7 Royalty Pharma 33.72 Bn 35.84 Bn - 62.96 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 65.13 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 104.44 Mn
10 Vaxcyte 8.41 Bn 8.41 Bn - 192.56 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 192.56 Mn
Mar 31, 2026 1.47 Mn
Dec 31, 2025 1.47 Mn
Sep 30, 2025 1.47 Mn
Jun 30, 2025 1.32 Mn
Mar 31, 2025 1.32 Mn
Dec 31, 2024 1.32 Mn
Sep 30, 2024 1.32 Mn
Jun 30, 2024 1.10 Mn
Mar 31, 2024 1.10 Mn
Dec 31, 2023 1.10 Mn
Sep 30, 2023 1.10 Mn
Jun 30, 2023 3.48 Mn
Mar 31, 2023 871,000.00
Dec 31, 2022 871,000.00
Sep 30, 2022 871,000.00
Jun 30, 2022 5.43 Mn
Mar 31, 2022 5.67 Mn
Dec 31, 2021 4.09 Mn
Sep 30, 2021 3.58 Mn